Fuda Cancer Hospital
Ocrevus (ocrelizumab) in China typically costs from $14,200 to $19,500. The total price depends on hospital procurement and the specific city. In the United States, patients pay around $80,000 on average. China offers savings of approximately 79%. This treatment usually includes the medication, specialist consultations, and professional infusion administration in a clinical setting.
Bookimed Expert Insight: Seeking care at JCI-accredited facilities ensures international safety standards for complex biologic infusions. Fuda Cancer Hospital in Guangzhou is an example of such a high-tier facility. It has served over 30,000 international patients. Choosing established hospitals in medical hubs provides access to experienced neurologists. These specialists are crucial for managing long-term treatment protocols effectively and safely.
| China | Turkey | Austria | |
| Ocrevus (ocrelizumab) | from $14,200 | from $10,000 | from $35,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Ocrevus (ocrelizumab) upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Ocrevus (ocrelizumab) and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Ocrevus (ocrelizumab) journey.
Day 1: Arrival
Day 2: Pre-Operation
Day 3: Ocrevus (ocrelizumab) Infusion
Week 1-2: Post-Operation
Week 3-4: Rehabilitation
Please note that each patient"s experience with Ocrevus (ocrelizumab) can differ. Always consult with your healthcare team for personalized advice.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.